Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/7/2025 | $145.00 → $179.00 | Neutral → Buy | UBS |
| 2/26/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 2/13/2025 | $130.00 → $170.00 | Equal Weight → Overweight | Wells Fargo |
| 12/12/2024 | $140.00 → $175.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/5/2024 | $169.00 | Buy | Goldman |
| 1/3/2024 | $160.00 | Outperform | Robert W. Baird |
| 11/27/2023 | $170.00 → $135.00 | Buy → Neutral | UBS |
| 9/29/2023 | Mkt Perform | Raymond James |
UBS upgraded Jazz Pharma from Neutral to Buy and set a new price target of $179.00 from $145.00 previously
Cantor Fitzgerald downgraded Jazz Pharma from Overweight to Neutral
Wells Fargo upgraded Jazz Pharma from Equal Weight to Overweight and set a new price target of $170.00 from $130.00 previously
For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl
Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance setting Jazz to host investor webcast on Tuesday, June 10 at 4:30 p.m. EDT / 9:30 p.m. IST to review Zepzelca data For U.S. media and investors only DUBLIN, June 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as
First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium oxybate Novel intermediate analysis from the DUET trial cohort of patients taking >9 grams evaluated safety and changes in daytime sleepiness in adults with narcolepsy taking Xywav dosages of 9-12 grams per night For U.S. media and investors only DUBLIN, June 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced late-breaking Phase 4 data evaluating treatment benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in people with narcolepsy. These results are two of Jazz'
First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance Results presented at the ASCO 2025 Annual Meeting and simultaneously published in The Lancet Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data For U.S. media and investors only DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced positive re
DEFA14A - Jazz Pharmaceuticals plc (0001232524) (Filer)
DEF 14A - Jazz Pharmaceuticals plc (0001232524) (Filer)
144 - Jazz Pharmaceuticals plc (0001232524) (Subject)